These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15190019)

  • 1. Non-nucleoside inhibitors of the HCV polymerase.
    Sarisky RT
    J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibitors of hepatitis C virus replication.
    Neyts J
    Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.
    Waheed Y; Bhatti A; Ashraf M
    Infect Genet Evol; 2013 Mar; 14():247-57. PubMed ID: 23291407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
    Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
    Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.
    Olsen DB; Eldrup AB; Bartholomew L; Bhat B; Bosserman MR; Ceccacci A; Colwell LF; Fay JF; Flores OA; Getty KL; Grobler JA; LaFemina RL; Markel EJ; Migliaccio G; Prhavc M; Stahlhut MW; Tomassini JE; MacCoss M; Hazuda DJ; Carroll SS
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3944-53. PubMed ID: 15388457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
    Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
    Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
    Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and development of small molecule HCV antivirals.
    Ni ZJ; Wagman AS
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):446-59. PubMed ID: 15338954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
    Li H; Shi ST
    Future Med Chem; 2010 Jan; 2(1):121-41. PubMed ID: 21426049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.
    Randolph JT; Flentge CA; Huang PP; Hutchinson DK; Klein LL; Lim HB; Mondal R; Reisch T; Montgomery DA; Jiang WW; Masse SV; Hernandez LE; Henry RF; Liu Y; Koev G; Kati WM; Stewart KD; Beno DW; Molla A; Kempf DJ
    J Med Chem; 2009 May; 52(10):3174-83. PubMed ID: 19402666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
    Lin K; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection.
    Sheldon J; Barreiro P; Soriano V
    Expert Opin Investig Drugs; 2007 Aug; 16(8):1171-81. PubMed ID: 17685867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An efficient, asymmetric solid-phase synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
    Evans KA; Chai D; Graybill TL; Burton G; Sarisky RT; Lin-Goerke J; Johnston VK; Rivero RA
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2205-8. PubMed ID: 16455253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.